Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer
Introduction: Advanced non-small cell lung cancer (aNSCLC) is an incurable disease. The effort to develop treatments with more effective systemic agents continues. This has led to the FDA approval of one antibody–drug conjugate (ADC) and eight immune checkpoint inhibitors (ICIs) for patients with aN...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-01-01
|
| Series: | Cancer Treatment and Research Communications |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294223000345 |
| _version_ | 1797732896042123264 |
|---|---|
| author | Idoko Salifu Navneet Singh Maria Berraondo Jordi Remon Stephanie Salifu Eric Severson Angela Quintana Sandra Peiró Shakti Ramkissoon Laura Vidal Isagani Chico Kamal S. Saini |
| author_facet | Idoko Salifu Navneet Singh Maria Berraondo Jordi Remon Stephanie Salifu Eric Severson Angela Quintana Sandra Peiró Shakti Ramkissoon Laura Vidal Isagani Chico Kamal S. Saini |
| author_sort | Idoko Salifu |
| collection | DOAJ |
| description | Introduction: Advanced non-small cell lung cancer (aNSCLC) is an incurable disease. The effort to develop treatments with more effective systemic agents continues. This has led to the FDA approval of one antibody–drug conjugate (ADC) and eight immune checkpoint inhibitors (ICIs) for patients with aNSCLC. Areas covered: Due to the demonstrated efficacy of ADCs and ICIs in aNSCLC, treatment combining both agents merits attention. This article, therefore, explores the use of ADCs and ICIs in patients with NSCLC, assesses the scientific rationale for combination treatment, and provides an overview of ongoing trials. It also presents some early efficacy and safety results of such combination use. Expert opinion: It is not clear whether ADC-immunotherapy has a significant impact on those with a targetable oncogenic driver alteration since targeted therapies are effective. However, in aNSCLC without a targetable oncogenic driver alteration, the combination of ADCs and ICIs has potential and remains an area of active clinical research. |
| first_indexed | 2024-03-12T12:21:10Z |
| format | Article |
| id | doaj.art-f0c24e34428c42d1adf674ebc5a07d72 |
| institution | Directory Open Access Journal |
| issn | 2468-2942 |
| language | English |
| last_indexed | 2024-03-12T12:21:10Z |
| publishDate | 2023-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cancer Treatment and Research Communications |
| spelling | doaj.art-f0c24e34428c42d1adf674ebc5a07d722023-08-30T05:54:20ZengElsevierCancer Treatment and Research Communications2468-29422023-01-0136100713Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancerIdoko Salifu0Navneet Singh1Maria Berraondo2Jordi Remon3Stephanie Salifu4Eric Severson5Angela Quintana6Sandra Peiró7Shakti Ramkissoon8Laura Vidal9Isagani Chico10Kamal S. Saini11Labcorp Drug Development Inc., Princeton, NJ, USA; Corresponding author.Postgraduate Institute of Medical Education and Research, Chandigarh, IndiaLabcorp Drug Development Inc., Princeton, NJ, USAParis-Saclay University, department of Cancer Medicine, Gustave Roussy, Villejuif, FranceDix Hills, NY, USALabcorp Drug Development Inc., Princeton, NJ, USAVall d'Hebron Institute of Oncology, Barcelona, SpainVall d'Hebron Institute of Oncology, Barcelona, SpainLabcorp Drug Development Inc., Princeton, NJ, USA; Department of Pathology, Wake Forest School of Medicine and Comprehensive Cancer Center, Winston-Salem, NC, USALabcorp Drug Development Inc., Princeton, NJ, USALabcorp Drug Development Inc., Princeton, NJ, USALabcorp Drug Development Inc., Princeton, NJ, USA; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UKIntroduction: Advanced non-small cell lung cancer (aNSCLC) is an incurable disease. The effort to develop treatments with more effective systemic agents continues. This has led to the FDA approval of one antibody–drug conjugate (ADC) and eight immune checkpoint inhibitors (ICIs) for patients with aNSCLC. Areas covered: Due to the demonstrated efficacy of ADCs and ICIs in aNSCLC, treatment combining both agents merits attention. This article, therefore, explores the use of ADCs and ICIs in patients with NSCLC, assesses the scientific rationale for combination treatment, and provides an overview of ongoing trials. It also presents some early efficacy and safety results of such combination use. Expert opinion: It is not clear whether ADC-immunotherapy has a significant impact on those with a targetable oncogenic driver alteration since targeted therapies are effective. However, in aNSCLC without a targetable oncogenic driver alteration, the combination of ADCs and ICIs has potential and remains an area of active clinical research.http://www.sciencedirect.com/science/article/pii/S2468294223000345 |
| spellingShingle | Idoko Salifu Navneet Singh Maria Berraondo Jordi Remon Stephanie Salifu Eric Severson Angela Quintana Sandra Peiró Shakti Ramkissoon Laura Vidal Isagani Chico Kamal S. Saini Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer Cancer Treatment and Research Communications |
| title | Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer |
| title_full | Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer |
| title_fullStr | Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer |
| title_full_unstemmed | Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer |
| title_short | Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer |
| title_sort | antibody drug conjugates immune checkpoint inhibitors and their combination in advanced non small cell lung cancer |
| url | http://www.sciencedirect.com/science/article/pii/S2468294223000345 |
| work_keys_str_mv | AT idokosalifu antibodydrugconjugatesimmunecheckpointinhibitorsandtheircombinationinadvancednonsmallcelllungcancer AT navneetsingh antibodydrugconjugatesimmunecheckpointinhibitorsandtheircombinationinadvancednonsmallcelllungcancer AT mariaberraondo antibodydrugconjugatesimmunecheckpointinhibitorsandtheircombinationinadvancednonsmallcelllungcancer AT jordiremon antibodydrugconjugatesimmunecheckpointinhibitorsandtheircombinationinadvancednonsmallcelllungcancer AT stephaniesalifu antibodydrugconjugatesimmunecheckpointinhibitorsandtheircombinationinadvancednonsmallcelllungcancer AT ericseverson antibodydrugconjugatesimmunecheckpointinhibitorsandtheircombinationinadvancednonsmallcelllungcancer AT angelaquintana antibodydrugconjugatesimmunecheckpointinhibitorsandtheircombinationinadvancednonsmallcelllungcancer AT sandrapeiro antibodydrugconjugatesimmunecheckpointinhibitorsandtheircombinationinadvancednonsmallcelllungcancer AT shaktiramkissoon antibodydrugconjugatesimmunecheckpointinhibitorsandtheircombinationinadvancednonsmallcelllungcancer AT lauravidal antibodydrugconjugatesimmunecheckpointinhibitorsandtheircombinationinadvancednonsmallcelllungcancer AT isaganichico antibodydrugconjugatesimmunecheckpointinhibitorsandtheircombinationinadvancednonsmallcelllungcancer AT kamalssaini antibodydrugconjugatesimmunecheckpointinhibitorsandtheircombinationinadvancednonsmallcelllungcancer |